NCT05134454Active, not recruiting
Atrial Fibrillation Screening Post Ischemic Cerebrovascular Events
A Multicenter, National, Investigator-initiated, Randomized, Parallel-group, Registerbased Superiority Study to Compare Extended ECG Monitoring Versus Standard ECG Monitoring of 1-2 Days in Elderly Patients With Ischemic Stroke or TIA.
Source: ClinicalTrials.gov · Last updated 5 Aug 2026
Brief summary (registry, in English)
Stroke is one of the leading causes behind death and permanent disability in adults. Atrial fibrillation (AF) is the most common clinical arrhythmia and its prevalence is steeply increasing with age. Atrial fibrillation is associated with a manifold increase in the risk for stroke. It is considered important to investigate the heart rhythm in stroke survivors without previously known AF, because detection of AF will prompt a change in antithrombotic treatment with subsequent lowering of the risk of recurrent stroke. There are so far very few studies on the prognostic impact of ECG investigations post stroke. Despite this knowledge gap, ECG investigation post stroke is given high priority in national and international guidelines. Considerable clinical resources are currently invested in these ECG investigations without knowledge of its utility. The investigators plan a nationwide, randomised, register-based study (RRCT) including patients aged at least 70 years receiving in-hospital care for stroke or TIA (Transient Ischemic Attack). Included patients will be randomised to standard investigation (1-2 days of ECG ) or extended ECG investigation (14 days of ECG performed at least twice). Patients diagnosed AF will be offered anticoagulation treatment. Long-term follow-up will be performed via swedish health care registers. The result of this trial will have major impact on the ECG screening recommendations for patients who have had stroke, a large group of patients with dismal prognosis.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 3300 (estimated)
- First submitted
- 20 Sept 2021
- Start date
- 20 Jan 2022
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Karolinska Institutet
- Diseases
- Stroke, Atrial fibrillation
- NCT number
- NCT05134454
What you commit to
- Study type: Interventional
- Planned participants: 3300
- From 20 Jan 2022 to the primary completion date, 31 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previously diagnosed atrial fibrillation
- Dual antiplatelet therapy not interchangeable to oral anticoagulation
Other illness
- Indication for anticoagulant treatment other than atrial fibrillation, e.g. venous thromboembolism or mechanical heart valve prosthesis
- Patients with pacemaker, implantable cardioverter defibrillator or implantable cardiac monitor.
Other
- Contraindication to oral anticoagulant treatment according to Summary of Product Characteristics.
- Patients who, according to the investigator, will not be able to comply with the study protocol.
Who the study is looking for
- Patients aged ≥ 70 years
- A diagnosis of ischemic stroke or TIA within 14 days from inclusion.
Age in the registry: 70 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Karolinska Institutet Danderyds University Hospital Coordinator of this site? Confirm its status | Stockholm | Sweden | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.